Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | STAT6 | P42226 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 5/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PRKAG1 | P54619 | 6/20 | 0.33 |
| ▸ | PRKAB1 | Q9Y478 | 6/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1636637 | 0.90 | CACNA1G (0.36) | LMNAKDM4EGMNNMAPTBLM | |
| SCHEMBL1635562 | 0.78 | AR (0.41) | LMNAKDM4EGMNNMAPTBLM | |
| SCHEMBL1635572 | 0.76 | AR (0.39) | LMNAKDM4EGMNNMAPTBLM | |
| SCHEMBL1635575 | 0.67 | AR (0.38) | LMNAKDM4EGMNNMAPTBLM | |
| SCHEMBL4757788 | 0.67 | AR (0.38) | LMNAKDM4EGMNNMAPTBLM | |
| SCHEMBL4819709 | 0.67 | AR (0.38) | LMNAKDM4EGMNNMAPTBLM | |
| SCHEMBL1636557 | 0.67 | AR (0.42) | LMNACACNA1GCACNA1HARGAA | |
| SCHEMBL12463105 | 0.60 | CSNK1D (0.43) | CYP3A4 | |
| SCHEMBL12395270 | 0.60 | FABP6 (0.30) | — | |
| SCHEMBL8136599 | 0.60 | LMNA (0.60) | LMNAKDM4EGMNNMAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120830-B2 | 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-01 | — | — | US | disclosed |
| US-9120830-B2 | 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-01 | — | — | US | disclosed |
| US-9120830-B2 | 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-01 | — | — | US | disclosed |
| US-20140309261-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-16 | — | — | US | disclosed |
| US-20140309261-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-16 | — | — | US | disclosed |
| US-20140309261-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-16 | — | — | US | disclosed |
| US-8802865-B2 | 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2014-08-12 | — | — | US | disclosed |
| US-8802865-B2 | 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2014-08-12 | — | — | US | disclosed |
| US-8802865-B2 | 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2014-08-12 | — | — | US | disclosed |
| US-20140031317-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-30 | — | — | US | disclosed |
| EP-1984343-B1 | 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-27 | — | — | EP | disclosed |
| US-20110166102-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ALFORD JR VERNON C | 2011-07-07 | — | — | US | disclosed |
| US-20110166102-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ALFORD JR VERNON C | 2011-07-07 | — | — | US | disclosed |
| US-20110166102-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ALFORD JR VERNON C | 2011-07-07 | — | — | US | disclosed |
| US-7932399-B2 | 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-26 | — | — | US | disclosed |
| US-7932399-B2 | 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-26 | — | — | US | disclosed |
| US-7932399-B2 | 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-26 | — | — | US | disclosed |
| US-20070208014-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-06 | — | — | US | disclosed |
| US-20070208014-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-06 | — | — | US | disclosed |
| US-20070208014-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031317-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | LMNA 4047/4885KDM4E 819/4885GMNN 4279/4885 |
| US-20110166102-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | LMNA 4047/4885KDM4E 819/4885GMNN 4279/4885 |
| US-20070208014-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | LMNA 4047/4885KDM4E 819/4885GMNN 4279/4885 |
| US-20140309261-A1 | NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | LMNA 4047/4885KDM4E 819/4885GMNN 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.